Østergaard, Jakob Appel
Jansson Sigfrids, Fanny
Forsblom, Carol
Dahlström, Emma H.
Thorn, Lena M.
Harjutsalo, Valma
Flyvbjerg, Allan
Thiel, Steffen
Hansen, Troels Krarup
Groop, Per-Henrik http://orcid.org/0000-0003-4055-6954
Funding for this research was provided by:
Danish Diabetes Association
Danish Council for Independent Research
Health Research Fund of Central Denmark Region
Folkhälsan Research Foundation
Wilhelm and Else Stockmann Foundation
Päivikki and Sakari Sohlberg Foundation
Medical Society of Finland
Finnish Diabetes Research Foundation
“Liv och Hälsa” Society
Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns Minne
Academy of Finland (316664)
Novo Nordisk Foundation (OC0013659)
HUH state research funding (TYH2018207)
Finnish Foundation for Cardiovascular Research
Article History
Received: 25 September 2020
Accepted: 31 March 2021
First Online: 26 April 2021
Competing interests
: P.-H.G. has received research grants from Eli Lilly and Roche, lecture fees from Astellas, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi, and SCIARC. He is an advisory board member for AbbVie, Astellas, Astra Zeneca, Bayer, Boehringer-Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. None of these entities participated in the design or interpretation of the study. No other potential conflicts of interest relevant to this article were reported.